Use of pristinamycin for Macrolide-Resistant mycoplasma genitalium infection

Tim R.H. Read, Jørgen S. Jensen, Christopher K. Fairley, Mieken Grant, Jennifer A. Danielewski, Jenny Su, Gerald L. Murray, Eric P.F. Chow, Karen Worthington, Suzanne M. Garland, Sepehr N. Tabrizi, Catriona S. Bradshaw

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)

Abstract

High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.

Original languageEnglish
Pages (from-to)328-335
Number of pages8
JournalEmerging Infectious Diseases
Volume24
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Cite this